Liquid Chromatography Tandem Mass Spectrometry

液相色谱串联质谱法

• 批准号: 7595708
• 负责人: CHRISTINA C. WANG
• 金额: $ 48.74万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7595708
• 关键词: Arts; Biological Assay; Biomedical Research; Bone Diseases; California; Chemicals; Child; Clinical; Clinical Research; Core Facility; Diagnosis; Disease; Elderly; Endocrine; Equipment; Funding; HIV; Health Sciences; Hormonal; Hormones; Human; Immunoassay; Institutes; Institution; Joints; Kidney; Laboratories; Liquid Chromatography; Liquid substance; Los Angeles; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Measures; Medical center; Metabolic; Metabolic Bone Diseases; Metabolism; Methodology; Methods; Monitor; Morbidity - disease rate; Preparation; Protocols documentation; Reproducibility; Research; Research Institute; Research Personnel; Serum; Services; Sister; Technology; Translational Research; Underserved Population; United States National Institutes of Health; Universities; Vitamin Deficiency; Vitamins; Woman; mass spectrometer; men; patient population; programs; public health relevance; small molecule; tandem mass spectrometry

DESCRIPTION (provided by applicant): The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA Biomed) General Clinical Research Center (GCRC) is applying for a Liquid Chromatography Tandem Mass Spectrometer (LC-MS/MS) for the GCRC Core Laboratory and the Biomedical Mass Spectrometry Facility. The LC/MS/MS is requested to serve the needs of clinical and translational investigators at Harbor-LA Biomed and our sister institutions in Los Angeles (Cedars Sinai Medical Center (Cedars-Sinai), UCLA-Westwood, and the Charles Drew University of Health and Science (Drew)). The sharing of the services of this equipment is an important part of our preparation for a joint application for a Clinical and Translational Sciences Institute (CTSI) across the four sister institutions. To avoid duplication, increase efficiency and optimize utilization in the laboratory, the program and laboratories directors of the GCRCs at UCLA Westwood, Cedars-Sinai, Harbor-LA Biomed and Drew have agreed to designate the Harbor-UCLA GCRC Core Lab and Biomedical Mass Spectrometry facility as the central Endocrine and Metabolism Core Laboratory for all four CTSI institutions. Currently, the GCRC Core Laboratory provides hormone and vitamin analyses mostly by immunoassays. These methodologies have higher variance, poorer reproducibility and in many instances less accuracy than that obtained from LC/MS/MS. The challenges of clinical assays of small molecules in research include the requirements of high sensitivity and low limit of quantitation (LOQ) into the low fentomolar range. Such sensitivity is necessary in order to be able to accurately diagnose hormonal or vitamin deficiency and to monitor its treatment in men, women and children. Our current investigators include 6 major NIH users with 15 protocols, 9 NIH funded users and 6 other junior and funded investigators. These investigators are engaged in a wide spectrum of research spanning from metabolic bone diseases inflicting children and the elderly, hormonal deficiencies in men and women, hormone and non-hormone dependent cancers, co-morbidities of HIV disease and importantly, understanding mechanisms underlying these diseases. With expansion of validated assay portfolio we anticipate that we can support more than twice the research protocols. This application is strongly supported by all four participating institutions. The strengthening of the Core Facilities providing Mass Spectrometry Technology capability will also significantly enhance our ability to serve not only our institution but our sister institutions at UCLA, Cedars-Sinai, and Drew in Southern California and our diverse and often underserved patient population. PUBLIC HEALTH RELEVANCE: The Harbor-UCLA General Clinical Research Center is requesting the funding of a state of the art, high-throughput liquid chromatography tandem mass spectrometer to measure serum hormones and other metabolic products in human bodily fluids. This will allow the measurement of very small amounts of these hormones and chemicals with very high selectivity, accuracy and precision. The application of this method will support many investigators from LA BioMed, Cedars-Sinai, UCLA-Westwood and Drew University in the diagnosis and monitoring of treatment of many metabolic, endocrine, kidney an bone disease for our underserved population.

描述（由申请人提供）：位于Harbor-UCLA医学中心（LA Biomed）的洛杉矶生物医学研究所（GCRC）正在为GCRC核心实验室和生物医学质谱设施申请液相色谱串联质谱仪（LC-MS/MS）。要求LC/MS/MS满足Harbor-LA Biomed和我们在洛杉矶的姐妹机构（Cedars Sinai Medical Center（Cedars-Sinai）、UCLA-Westwood和Charles Drew University of Health and Science（Drew））的临床和翻译研究者的需求。共享这些设备的服务是我们准备在四个姐妹机构之间联合申请临床和转化科学研究所（CTSI）的重要组成部分。为了避免重复，提高效率并优化实验室的利用率，UCLA Westwood，Cedars-Sinai，Harbor-LA Biomed和Drew的GCRC的项目和实验室主任同意指定Harbor-UCLA GCRC核心实验室和生物医学质谱设施为所有四个CTSI机构的中央内分泌和代谢核心实验室。目前，GCRC核心实验室主要通过免疫测定法提供激素和维生素分析。这些方法具有较高的方差，较差的再现性，并在许多情况下，从LC/MS/MS获得的准确度较低。在研究中的小分子的临床测定的挑战包括高灵敏度和低定量限（LOQ）的要求到低fentomolar范围。这种敏感性是必要的，以便能够准确诊断激素或维生素缺乏症，并监测其在男子，妇女和儿童的治疗。我们目前的研究人员包括6个主要的NIH用户，15个协议，9个NIH资助的用户和6个其他初级和资助的研究人员。这些研究人员从事广泛的研究，包括影响儿童和老年人的代谢性骨病，男性和女性的激素缺乏症，激素和非激素依赖性癌症，艾滋病毒疾病的并发症，重要的是，了解这些疾病的机制。随着经验证的检测产品组合的扩展，我们预计我们可以支持两倍以上的研究方案。这项申请得到了所有四个参与机构的大力支持。提供质谱技术能力的核心设施的加强也将显着提高我们的服务能力，不仅是我们的机构，但我们的姐妹机构在加州大学洛杉矶分校，雪松-西奈半岛，德鲁在南加州和我们的多样化，往往服务不足的患者群体。公共卫生相关性：Harbor-UCLA综合临床研究中心正在申请资助最先进的高通量液相色谱串联质谱仪，以测量人体体液中的血清激素和其他代谢产物。这将允许以非常高的选择性、准确性和精确度测量非常少量的这些激素和化学物质。该方法的应用将支持来自LA BioMed，Cedars-Sinai，UCLA-Westwood和Drew University的许多研究人员为我们服务不足的人群诊断和监测许多代谢，内分泌，肾脏和骨骼疾病的治疗。